- Report
- October 2024
- 198 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- October 2024
- 199 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 182 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 137 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- January 2024
- 157 Pages
Global
From €4232EUR$4,650USD£3,628GBP
- Report
- December 2021
- 95 Pages
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- October 2023
- 81 Pages
United Kingdom
From €3185EUR$3,500USD£2,731GBP
- Report
- February 2022
- 76 Pages
Europe
From €1365EUR$1,500USD£1,170GBP
- Report
- January 2025
- 88 Pages
Global
From €3500EUR$4,120USD£3,106GBP
The Prostate Health market is a subset of the pharmaceutical industry focused on the development and sale of drugs to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it are typically hormone therapy, chemotherapy, and radiation therapy. These drugs are used to reduce the size of the tumor, slow its growth, and reduce the risk of metastasis. In addition, some drugs are used to reduce the side effects of prostate cancer treatments, such as fatigue, nausea, and sexual dysfunction.
The Prostate Health market is highly competitive, with many companies offering a variety of drugs to treat prostate cancer. Some of the major players in the market include AstraZeneca, Pfizer, Merck, and Johnson & Johnson. Other companies in the market include AbbVie, Bristol-Myers Squibb, and Sanofi. Show Less Read more
